Conference Correspondent
News, views, and coverage of important topics and discussions from oncology conferences and events.
Resistance to the combination of osimertinib plus savolitinib is predominantly mediated by acquired mutations in either MET, EGFR, or KRAS in patients with EGFR-mutated metastatic non–small-cell lung cancer (NSCLC). Read More ›
Based on results of the RATIONALE 303 trial, tislelizumab significantly prolonged median overall survival by more than 5 months in patients with advanced non–small-cell lung cancer (NSCLC) compared with docetaxel. Read More ›
Compared with docetaxel, sintilimab significantly prolonged median overall survival by more than 3 months in patients with advanced squamous non–small-cell lung cancer (NSCLC). Read More ›
In patients with advanced squamous non–small-cell lung cancer (NSCLC), the combination of bintrafusp alfa and chemotherapy was well tolerated. The most common treatment-related adverse events were anemia, nausea, and pruritus. Read More ›
Combining nivolumab with a limited course of chemotherapy in resectable non–small-cell lung cancer (NSCLC) enhances rates of pathologic complete response compared with chemotherapy alone. Read More ›
Findings of the prospective community-based observational NILE study support the use of cfDNA to identify actionable genomic alterations in newly diagnosed patients with advanced lung adenocarcinoma. Read More ›
Every year, researchers and clinicians report on exciting advancements in the diagnosis and treatment of cancer. In 2021, despite the COVID-19 pandemic, developments in the management of lung cancer continue to be important and intriguing. Read More ›
The LC-SCRUM-Asia project analysis indicated that utilization of rapid multigene assays in patients with advanced non–small-cell lung cancer (NSCLC) was associated with short turnaround times and high success rates compared with a targeted assay. Read More ›
Provider adherence to National Comprehensive Cancer Network recommendations and implementation of an automated regimen-level prior authorization is associated with lower cost and more efficient oncology care in patients with non–small-cell lung cancer. Read More ›
The majority of progressing stage IV non–small-cell lung cancer patients with development of resistance to targeted therapies benefit from repeat molecular profiling to detect actionable resistance mechanisms and facilitate clinical trial enrollment. Read More ›